SCHEMBL373931

SCHEMBL373931

CCCCCC(CCO)CC(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 10/20 0.55
LMNA P02545 1/20 0.48
FFAR1 O14842 3/20 0.44
FFAR4 Q5NUL3 2/20 0.44
PPARD Q03181 6/20 0.42
MAPT P10636 1/20 0.42
LCK P06239 1/20 0.42
ZDHHC20 Q5W0Z9 1/20 0.42
ZDHHC2 Q9UIJ5 1/20 0.42
AKR1B1 P15121 1/20 0.41
PPARG P37231 5/20 0.40
PPARA Q07869 5/20 0.40
HDAC11 Q96DB2 4/20 0.40
TSHR P16473 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TLR2 O60603 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
FABP4 P15090 2/20 0.40
PTPN1 P18031 2/20 0.40
SLC22A6 Q4U2R8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8991255 0.98 GPR84 (0.58) GPR84LMNAFFAR1FFAR4PPARD
SCHEMBL5171531 0.98 GPR84 (0.58) GPR84LMNAFFAR1FFAR4PPARD
SCHEMBL28834415 0.94 GPR84 (0.47) GPR84LMNAFFAR1FFAR4PPARD
SCHEMBL5203381 0.92 GPR84 (0.55) GPR84LMNAFFAR1FFAR4PPARD
Ethylene Glycol SCHEMBL5137218 0.92 GPR84 (0.60) GPR84LMNAFFAR1FFAR4PPARD
Ethylene Glycol SCHEMBL5137927 0.92 GPR84 (0.60) GPR84LMNAFFAR1FFAR4PPARD
Ethylene Glycol SCHEMBL5136577 0.92 GPR84 (0.60) GPR84LMNAFFAR1FFAR4PPARD
Ethylene Glycol SCHEMBL5138346 0.92 GPR84 (0.60) GPR84LMNAFFAR1FFAR4PPARD
SCHEMBL4597758 0.92 GPR84 (0.63) GPR84LMNAFFAR1FFAR4PPARD
SCHEMBL7202803 0.90 GPR84 (0.58) GPR84LMNAFFAR1FFAR4PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111351867-B Analysis method for determining substances related to lubiprostone test sample 南京正大天晴制药有限公司 2021-06-29 CN claimed
WO-2020125027-A1 ANALYSIS METHOD FOR DETERMINING SUBSTANCE RELATED TO LUBIPROSTONE TEST SAMPLE 南京正大天晴制药有限公司 2020-06-25 WO claimed
CN-103739481-A Method for splitting naproxen employing chiral stationary phase UNIV MINNAN NORMAL 2014-04-23 CN claimed
CN-115047127-B Method for identifying NFC and FC orange juice by utilizing volatile metabonomics technology 中国检验检疫科学研究院 2024-03-08 CN disclosed
CN-111351867-B Analysis method for determining substances related to lubiprostone test sample 南京正大天晴制药有限公司 2021-06-29 CN disclosed
CN-111351867-A Analysis method for determining substances related to lubiprostone test sample 南京正大天晴制药有限公司 2020-06-30 CN disclosed
WO-2020125027-A1 ANALYSIS METHOD FOR DETERMINING SUBSTANCE RELATED TO LUBIPROSTONE TEST SAMPLE 南京正大天晴制药有限公司 2020-06-25 WO disclosed
US-8901319-B2 Process for the preparation of F-series prostaglandins CAYMAN CHEMICAL COMPANY, INCORPORATED (US) 2014-12-02 US disclosed
CN-103739481-A Method for splitting naproxen employing chiral stationary phase UNIV MINNAN NORMAL 2014-04-23 CN disclosed
US-20120295004-A1 CRYSTALS OF NON-NATURAL-TYPE STEREOISOMER SALT OF MONATIN AND USE THEREOF AJINOMOTO CO., INC. (JP) 2012-11-22 US disclosed
US-20120283451-A1 PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS CAYMAN CHEMICAL COMPANY, INCORPORATED 2012-11-08 US disclosed
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides SCHERING AKTIENGESELLSCHAFT 2002-01-03 US disclosed
EP-0778269-B1 PROSTAGLANDINS AND PROCESS FOR PRODUCING THE SAME TEIJIN LTD (JP) 2000-09-27 EP disclosed
US-5990346-A AN INHIBITORS OF CELL MIGRATION CAUSED BY CHEMOKINES TEIJIN LIMITED (JP) 1999-11-23 US disclosed
US-5760238-A ANTIISCHEMIC AGENTS MERCIAN CORPORATION (JP) 1998-06-02 US disclosed
EP-0779277-A1 1,4-DIHYDROPYRIDINE DERIVATIVE MERCIAN CORPORATION (JP) 1997-06-18 EP disclosed
EP-0778269-A1 PROSTAGLANDINS AND PROCESS FOR PRODUCING THE SAME TEIJIN LIMITED (JP) 1997-06-11 EP disclosed
EP-0003583-B1 COMPOSITIONS FOR CYTOCHEMICAL INVESTIGATION, THEIR USE AND METHOD FOR THE DETECTION OF STEROID HORMONE RECEPTORS IN HUMAN TISSUES Lee, Sin Hang (US) 1981-12-02 EP disclosed
US-4204001-A PROSTAGLANDINS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1980-05-20 US disclosed
US-4115580-A PROSTAGLANDINS, LUTEOLYSIS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295004-A1 CRYSTALS OF NON-NATURAL-TYPE STEREOISOMER SALT OF MONATIN AND USE THEREOF MON2, SRI, CROCC GPR84 1148/4885LMNA 2825/4885FFAR1 1545/4885
US-20120283451-A1 PROCESS FOR THE PREPARATION OF F-SERIES PROSTAGLANDINS PTGIS, PTGES, PTGFR GPR84 2978/4885LMNA 4008/4885FFAR1 241/4885
US-20020002274-A1 Process for the production of perbenzylated 1-0-glycosides STT3B, MAN1B1, OSTC GPR84 4311/4885LMNA 1629/4885FFAR1 1994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.